1. Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR status

2. Table S2: The survival events in each subgroup IBC: Inflammatory breast cancer nIBC: Non-inflammatory breast cancer OS: Overall survival DMFS: distant metastasis-free survival RFS: recurrence-free survival M: mesenchymal IM: immunomodulatory BL1: basal-like 1 BL2: basal-like 2 LAR: luminal androgen receptor UNS: unstable MSL: mesenchymal stem-like

3. Table S3: Patient characteristics for the 7 TNBC subtypes defined by Lehmann et al.’s signatures

4. Table S4: Patient characteristics for the 7 TNBC subtypes defined by our gene signatures

5. Table 5A: Distribution of IBC/non-IBC status by TNBC subtype using our gene signatures Table 5B: Distribution of IBC/non-IBC status by TNBC subtype using Lehmann’s gene signatures Table S5: The analysis from Table 2 with TNBC defined by IHC results instead of mRNA expression (N=63)

6. Figure S1A: Overall survival by subtype (IHC definition of TNBC) Figure S1B: Recurrence-free survival by subtype (IHC definition) Figure S1C: Distant metastasis-free survival by subtype (IHC definition) year

7. Figure S2: Box plots of AR gene expression levels in TNBC subtypes defined by our approximated gene signatures (left panel) or Lehmann’s gene signatures (right panel) Cluster defined by approximated gene signatures Cluster defined by Lehmann’s gene signatures Log intensity (batch effect removed) BL1 N=15 BL2 N=5 IM N=17 LAR N=7 M N=9 MSL N=4 UNS N=6 BL1 N=10 BL2 N=4 IM N=16 LAR N=6 M N=7 MSL N=5 UNS N=15 Figure S2: The analysis of Figure 2 with TNBC defined by IHC results instead of mRNA expression (N=63)